APA (7th ed.) Citation

Goetze, T., Vogel, A., Gonzalez Carmona, M., Habibzade, T., Reinecke, J., Adler, M., . . . Modest, D. (2025). 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. Annals of Oncology, 36, S140. https://doi.org/10.1016/j.annonc.2025.05.372

Chicago Style (17th ed.) Citation

Goetze, T.O, et al. "357P ADJUBIL: A Phase II Study of Durvalumab and Tremelimumab with or Without Capecitabine in ADJUvant BILiary Tract Cancer: The IKF/AIO-ADJUBIL Trial." Annals of Oncology 36 (2025): S140. https://doi.org/10.1016/j.annonc.2025.05.372.

MLA (9th ed.) Citation

Goetze, T.O, et al. "357P ADJUBIL: A Phase II Study of Durvalumab and Tremelimumab with or Without Capecitabine in ADJUvant BILiary Tract Cancer: The IKF/AIO-ADJUBIL Trial." Annals of Oncology, vol. 36, 2025, p. S140, https://doi.org/10.1016/j.annonc.2025.05.372.